With $500M-plus, a buy­out and two new bil­lion-dol­lar pacts, up­start Vir is ready to roll on in­fec­tious dis­eases

George Scan­gos has been busy since leav­ing Bio­gen’s helm and jump­ing to the start­up Vir Biotech­nol­o­gy in San Fran­cis­co. Now it’s time for the com­ing out par­ty, which in­volves de­vel­op­ment al­liances with two of the biotechs back at his for­mer base in Cam­bridge, MA. And ac­cord­ing to Scan­gos, Vir is still just get­ting start­ed in build­ing a whole new com­pa­ny.

To­day Scan­gos un­veiled a biotech buy­out, two bil­lion-dol­lar drug de­vel­op­ment deals to build the pipeline, more than $500 mil­lion in fi­nanc­ing from some high-rolling tech gam­blers and four aca­d­e­m­ic part­ner­ships at Vir, which has set out to cre­ate a new pipeline for in­fec­tious dis­ease drug de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER